GLP-1 Obesity Research: Regeneron reported Phase 2 COURAGE trial results showing trevogrumab (anti-GDF8/anti-myostatin) can prevent lean mass and muscle loss during semaglutide-induced weight loss, with plans to study trevogrumab plus GLP-1 therapies in older adults. Metabolic Drug Deal: Novo Nordisk agreed to license Hengrui’s HRS-1596, a phase 1-ready once-weekly oral GLP-1/GIP dual agonist candidate, in a deal worth up to US$2.6bn (excluding mainland China, Hong Kong, Macao and Taiwan). Macao Health Services: Macao Union Medical Center outlined holiday arrangements for National Day (Oct 1–2), with outpatient and some services closed while emergency, inpatient and hemodialysis continue. Food Safety Alert: Macao’s IAM ordered a recall and sales stop for a black truffle sauce product after heavy metal total arsenic exceeded limits; residents were urged to stop eating the affected batch. Local Health Support: Hong Kong’s Home Affairs Department opened temporary heat shelters with enhanced cooling, water access and support for vulnerable users during very hot weather. School Tech & Health Angle: A Macau Business report compared smartphone restrictions in schools, highlighting Mainland China’s nationwide approach aimed at reducing digital addiction. Clinical Pipeline Update: Antengene announced preclinical Cos-TCE platform results to be presented at SITC 2026. Macao Care & Community: The Hospital Authority held a flag-raising ceremony for the PRC’s 77th anniversary, reflecting ongoing public health institution engagement during national events.